

# Irritable Bowel Syndrome (IBS) Therapeutics: Market Research Report

<https://marketpublishers.com/r/IDE1C33F0ABEN.html>

Date: August 2011

Pages: 433

Price: US\$ 4,500.00 (Single User License)

ID: IDE1C33F0ABEN

## Abstracts

This report analyzes the worldwide markets for Irritable Bowel Syndrome (IBS) Therapeutics in US\$ Million.

The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World.

Annual estimates and forecasts are provided for the period 2009 through 2017.

Also, a six-year historic analysis is provided for these markets.

The report profiles 50 companies including many key and niche players such as Abbott Laboratories, Alimentary Health Limited, Edusa Pharmaceuticals, Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., Lexicon Pharmaceuticals, Pharmos Corporation, Salix Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., and Tioga Pharmaceuticals, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

## Contents

### **1.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS**

Study Reliability and Reporting Limitations  
Disclaimers  
Data Interpretation & Reporting Level  
Quantitative Techniques & Analytics  
Product Definitions and Scope of Study

### **2.INDUSTRY OVERVIEW**

Irritable Bowel Syndrome: A Primer  
Market Analysis  
World IBS Market to Witness Substantial Growth Despite of Anticipated Slump in the GI Therapeutics Market  
New Drug Launches to Drive the Growth of Highly Underserved IBS Market in Developed Markets  
Select Drugs in Late Stage Clinical Development  
Linaclotide: One of the Most Promising Pipeline Drugs with Substantial Market Potential  
Irritable Bowel Syndrome Represents a Major Therapeutic Challenge  
Available IBS Drugs: Treating the Symptoms, Not the Cause  
A Comparison of Current and Previous Treatment for IBS  
Select Drugs/Therapeutics Available for IBS Treatment by Symptom  
Involvement of the Brain-Gut Axis Emphasized the Role of Serotonin in IBS  
Serotonin 5-HT Receptors Led the Drug Development Pipeline  
Lack of Selectivity Hampers Predominance of 5-HT Receptor Class of Drugs  
List of 5-HT Class Drug Withdrawals/Trial Failures  
Amitiza Led the IBS-C Market in 2008-2009, New Drug Launches Likely to Affect Sales  
Safety Concerns of Available Drugs and Low Rate of Diagnosis Limit Market Growth  
Growth Drivers  
IBS Market is Presently Highly Fragmented, Generalized, and Under Served  
Drug Development Programs Drive Market Growth in Developed Countries  
Product Co-development, Commercialization, and Licensing Agreements  
Other Growth Drivers  
High Prevalence  
Variable Diagnostic Criteria and IBS Prevalence  
Growing Awareness  
Multiple Treatment Approaches Make Way for Complementary Medicines

Need for Diagnostic Markers  
Development of Novel Therapies

### **3.DISEASE OVERVIEW**

Prevalence

**Table 1.** Prevalence of IBS in Select Countries/Regions of the World (includes corresponding Graph/Chart)

Prevalence by Gender: Higher Prevalence in Women  
Symptoms of IBS  
Comorbidities Associated with IBS  
Classification of IBS Based on Symptoms  
Diarrhea-predominant IBS or IBS-D  
Constipation-predominant IBS or IBS-C  
Alternating or Mixed Type IBS  
List of Select Conditions that could be Misdiagnosed as IBS  
Select Tests Recommended to Rule out GI Disorders Other than IBS  
What Causes Irritable Bowel Syndrome  
The Function of the Colon  
IBS and the Enteric Nervous System  
The Brain-Gut Interaction  
Direct Control  
Indirect Control  
Etiology of Irritable Bowel Syndrome  
Chronic Anxiety Mediated Visceral Hyperalgesia  
Serotonin  
5HT3 AND 5HT4 RECEPTORS  
Genetic Factors  
Gastrointestinal Infections  
The Intestinal Bacteria  
Diagnosis of Irritable Bowel Syndrome  
IBS Diagnostic Protocols  
The Rome III Criteria for IBS Diagnosis  
IBS Diagnosis in Children  
The Manning Criteria for IBS Diagnosis

## **4.TREATMENT OF IRRITABLE BOWEL SYNDROME (IBS)**

Current Treatment Scenario

Combination Therapies Offer Limited Efficacy and Short-Term Relief

An Overview of Select Treatment and Therapies for Irritable Bowel Syndrome

Select Drug Classes Available for IBS Treatment

Dietary Fiber

List of Select Commercially Packaged Fibers

Bulk-forming Laxatives

Osmotic laxatives

List of Select Osmotic Laxatives

Poorly Absorbed Ions

Poorly Absorbed Sugars

Stimulant laxatives

List of Select Stimulant Laxatives by Type

Derivatives of Diphenylmethane

Derivatives of Anthraquinones

Emollients

Anti-Diarrheals

Antidepressants

Scientific Data Supports the Use of Antidepressants in IBS

Tricyclics: Preferred Class of Antidepressants for Treating IBS

Side Effects of TCAs

Antispasmodic Agents

Anticholinergic Agents

List of Select Anticholinergics

Peppermint Oil and Direct Smooth Muscle Relaxants

List of Select Direct Smooth Muscle Relaxants

Alternative Therapies

Probiotics

What are probiotics?

Role of Probiotics

Potential Use of Probiotics in IBS Management

Data from Research and Clinical Studies

Herbal Remedies

Psychotherapy

Others

## **5.PRODUCT APPROVALS IN THE PAST**

Lotronex  
Zelnorm  
Amitiza  
BENTYL® (dicyclomine hydrochloride)  
Colpermin  
Irribow (Ramosetron Hydrochloride)

## **6.PIPELINE ANALYSIS**

Linaclotide  
LX1031  
XIFAXAN® (Rifaximin)  
ASIMADOLINE  
Drugs' Early Stage Clinical Trials  
Select IBS Drugs in Early Stages of Clinical Trials  
Review of Pipeline Drugs in the Past (2006)

## **7.CLINICAL TRIALS**

Synergy Pharmaceuticals to Conduct Phase II/III Trial of Plecanatide  
Almirall and Ironwood Achieve Success in Second Phase III Trial of Linaclotide in IBS-C  
Oxy-Powder Demonstrates Success in IBS Test  
Ironwood and Forest Achieve Positive Results in Phase 3 Trial of Linaclotide  
VSL 3 Proves Effective for Children Suffering from IBS  
Salix's Xifaxan (Rifaximin) Found Effective on Non-C IBS Symptom  
Lexicon Concludes Phase II Clinical Trial of LX1031  
Ocera Achieves Positive Result in Phase 2 Proof-of-Concept Trial of AST-120  
Pharmos Achieves Positive Results in Phase 2b IBS Trial  
Order-Made Souyaku to Commence IBS Drug Trials in the UK

## **8.RECENT INDUSTRY ACTIVITY**

Tioga Receives Fast Track Status for Asimadoline in IBS-D  
Canadian Institut Rosell Extends Partnership with Probi  
Achieve Clinical Research Commences Clinical Trials for IBS  
Wild Partners with Sterling Technology  
AMRI Proposes New Drug For IrriTable Bowel Syndrome  
Salix Obtains FDA's Filing and Priority Review Approval for XIFAXAN550 in Non-C IBS

Soligenix Receives US Patent for Beclomethasone Dipropionate for IBS Treatment  
Meda Takes Over Norgine's Over-the-Counter Drugs  
Tioga Reaches Agreement with FDA For Phase 3 Trials Of Asimadoline  
Sucampo Files 'Demand for Arbitration' Against Takeda  
Abbott Takes Over Solvay Pharmaceuticals  
SK Holdings Obtains IND Approval from FDA for YKP10811  
MicroDose Takes Over Epix's Portfolio of Compounds  
PPD Inks Agreement with Janssen Pharmaceutica  
Warner Chilcott Takes Over P&G's Global Branded Prescription Pharmaceutical Business  
Abbott Acquires Solvay's Pharmaceutical Business  
Tioga and Ono Ink Licensing Agreement for IBS Drug Development  
Lexicon Reacquires Joint Venture Rights from Symphony  
Ironwood Enters into Partnership with Almirall  
Pawfect Foods Takes Over Synergy Pharmaceuticals  
Tioga and US FDA Agree on SPA for Phase 3 Efficacy Protocols of Asimadoline in IBS-D  
Sucampo Obtains FDA Approval for AMITIZA for IBS-C in Adult Women  
Apex and Dynogen Dissolve Merger Agreement  
Rose Pharma and Eli Lilly Ink Licensing Agreement Pertaining to Compound for IBS Treatment  
Napo and Trine Terminate License Agreement for Crofelemer

## **9.PRODUCT INTRODUCTIONS/INNOVATIONS**

Cedars-Sinai Medical Center Introduces Rifaximin for IBS Patients  
Lesaffre Introduces Probiotic Yeast to Treat Intestinal Discomfort  
Lifeway Foods Launches BioKefir Range of Probiotic Drinks  
Mayo Clinic Discovers Novel Genetic Variants in Serotonin Genes  
Jarrow Formulas® to Introduce Ideal Bowel Support 299v®  
Buscopan Launches Online Interactive Resource for IBS Patient  
Chongqing Fortune Introduces Traditional Chinese Medicine  
Alimentary Health to Introduce New Probiotic Treatment  
Alimentary Health to Launch IBS Treatment  
Astellas Pharma Introduces Irribow for Irritable Bowel Syndrome

## **10.FOCUS ON SELECT PLAYERS**

Abbott Laboratories (US)

Alimentary Health Limited (Ireland)  
Edusa Pharmaceuticals (US)  
Ironwood Pharmaceuticals, Inc. (US)  
Forest Laboratories, Inc. (US)  
Lexicon Pharmaceuticals (US)  
Pharmos Corporation (US)  
Salix Pharmaceuticals, Inc. (US)  
Sucampo Pharmaceuticals, Inc. (US)  
Tioga Pharmaceuticals, Inc. (US)

## 11. GLOBAL MARKET PERSPECTIVE

**Table 2.** World Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) by Geographic Region – US, Japan, Europe, Rest of World Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 3.** World Historic Review for Irritable Bowel Syndrome (IBS) by Geographic Region – US, Japan, Europe, and Rest of World Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 4.** World 15-Year Perspective for Irritable Bowel Syndrome (IBS) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

## 12. THE UNITED STATES

### A. MARKET ANALYSIS

An Overview

Prevalence of IBS-C in the US

US Leads the Global IBS Drug Development Scenario

High Unmet Needs Characterize the IBS Market

New Drug Releases Likely to Drive Market Growth in the Near Future

Irritable Bowel Syndrome: Key Facts

Drugs Approved for Use in IBS Treatment

Amitiza

Zelnorm  
Lotronex  
Strategic Corporate Developments  
Focus on Select Major Players  
Abbott Laboratories (US)  
Edusa Pharmaceuticals (US)  
Ironwood Pharmaceuticals, Inc. (US)  
Forest Laboratories, Inc. (US)  
Lexicon Pharmaceuticals (US)  
Pharmos Corporation (US)  
Salix Pharmaceuticals, Inc. (US)  
Sucampo Pharmaceuticals, Inc. (US)  
Tioga Pharmaceuticals, Inc. (US)  
B. Market analytics

**Table 5.** The US Recent Past, Current & Future Analysis for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 6.** The US Historic Review for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

### 13.JAPAN

A. Market analysis  
Strategic Corporate Development  
Product Introductions/Innovation  
B. Market analytics

**Table 7.** Japanese Recent Past, Current & Future Analysis for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 8.** Japanese Historic Review for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

## 14.EUROPE

### Market Analysis

**Table 9.** European Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) by Geographic Region – France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 10.** European Historic Review for Irritable Bowel Syndrome (IBS) by Geographic Region – France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 11.** European 15-Year Perspective for RNA Interference Application by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

## 14A.FRANCE

### Market Analysis

**Table 12.** French Recent Past, Current & Future Analysis for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 13.** French Historic Review for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

## 14B.GERMANY

### Market Analysis

**Table 14.** German Recent Past, Current & Future Analysis for Irritable Bowel

Syndrome Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 15.** German Historic Review for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

## **14C.ITALY**

Market Analysis

**Table 16.** Italian Recent Past, Current & Future Analysis for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 17.** Italian Historic Review for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

## **14D.THE UNITED KINGDOM**

A. Market analysis

Product Introductions/Innovation

B. Market analytics

**Table 18.** The UK Recent Past, Current & Future Analysis for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 19.** The UK Historic Review for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

## **14E.SPAIN**

A. Market analysis

Strategic Corporate Development

## B. Market analytics

**Table 20.** Spanish Recent Past, Current & Future Analysis for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 21.** Spanish Historic Review for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

## 14F.RUSSIA

### Market Analysis

**Table 22.** Russian Recent Past, Current & Future Analysis for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 23.** Russian Historic Review for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

## 14G.REST OF EUROPE

### A. Market analysis

Strategic Corporate Developments

Product Introductions/Innovations

Focus on Select Key Player

Alimentary Health Limited (Ireland)

### B. Market analytics

**Table 24.** Rest of European Recent Past, Current & Future Analysis for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 25.** Rest of European Historic Review for Irritable Bowel Syndrome Market

Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

## **15.REST OF WORLD**

### A. Market analysis

Strategic Corporate Developments

Product Introductions/Innovation

### B. Market analytics

**Table 26.** Rest of World Recent Past, Current & Future Analysis for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 27.** Rest of World Historic Review for Irritable Bowel Syndrome Market Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Total Companies Profiled: 50 (including Divisions/Subsidiaries - 51)

Region/Country/Players

The United States

Canada

Japan

Europe

France

Germany

The United Kingdom

Italy

Spain

Rest of Europe

Asia-Pacific (Excluding Japan)

## I would like to order

Product name: Irritable Bowel Syndrome (IBS) Therapeutics: Market Research Report

Product link: <https://marketpublishers.com/r/IDE1C33F0ABEN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IDE1C33F0ABEN.html>